Assessment of the Safety of a New Thrombolytic: TNK-tPA - ASSENT-1

Description:

The Assessment of the Safety of a New Thrombolytic: TNK-tPA (ASSENT-1) trial was a Phase II dose-ranging trial that was designed to test the clinical safety of three different doses of tenecteplase-tissue plasminogen activator (TNK-tPA) in ST-elevation myocardial infarction (MI).